Treatment patterns in patients with rheumatoid arthritis initiating a JAK inhibitor or a TNF inhibitor based on retail pharmacies drug-dispensing data

Jessica Sambourg; Amandine Gouverneur; Isabelle Bardoulat; Thierry Schaeverbeke; Marie-Elise Truchetet; Milka Maravic

doi:10.1016/j.jbspin.2023.105629

Treatment patterns in patients with rheumatoid arthritis initiating a JAK inhibitor or a TNF inhibitor based on retail pharmacies drug-dispensing data

Joint Bone Spine. 2023 Dec;90(6):105629. doi: 10.1016/j.jbspin.2023.105629. Epub 2023 Aug 25.

Authors

Jessica Sambourg¹, Amandine Gouverneur², Isabelle Bardoulat³, Thierry Schaeverbeke⁴, Marie-Elise Truchetet⁴, Milka Maravic⁵

Affiliations

¹ IQVIA, General Management, Courbevoie, France.
² IQVIA, Real World Solutions, Bordeaux, France.
³ IQVIA, Real World Solutions, Courbevoie, France.
⁴ Departement of Rheumatology, Pellegrin Hospital, Bordeaux, France.
⁵ IQVIA, General Management, Courbevoie, France; Department of Rheumatology, Lariboisière Hospital, AP-HP, Paris, France. Electronic address: [email protected].

PMID: 37634873
DOI: 10.1016/j.jbspin.2023.105629

No abstract available

Keywords: Arthritis; Comparative study; Janus kinase inhibitors; Postmarketing; Product surveillance; Rheumatoid; Tumor necrosis factor inhibitors.

Publication types

Letter

MeSH terms

Antirheumatic Agents* / therapeutic use
Arthritis, Rheumatoid* / drug therapy
Humans
Janus Kinase Inhibitors* / therapeutic use
Pharmacies*
Tumor Necrosis Factor Inhibitors / therapeutic use
Tumor Necrosis Factor-alpha / therapeutic use

Substances

Janus Kinase Inhibitors
Tumor Necrosis Factor Inhibitors
Tumor Necrosis Factor-alpha
Antirheumatic Agents